We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+5.15%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$165M
AUM Growth
-$22.1M
Cap. Flow
-$24.2M
Cap. Flow %
-14.7%
Top 10 Hldgs %
76.79%
Holding
40
New
10
Increased
2
Reduced
11
Closed
15

Top Buys

1
HTGM
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
+$6.12M
2
RIGL icon
Rigel Pharmaceuticals
RIGL
+$5.33M
3
ADMA icon
ADMA Biologics
ADMA
+$4.15M
4
ATXS
Astria Therapeutics
ATXS
+$3.69M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.48M

Top Sells

1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$6.43M
2
BSTC
BioSpecifics Technologies Corp.
BSTC
+$5.54M
3
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$5.26M
4
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$4.99M
5
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$4.78M

Sector Composition

1 Healthcare 99.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSTC
1
DELISTED
BioSpecifics Technologies Corp.
BSTC
$20.7M 12.58%
461,315
-128,710
-22% -$5.54M
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$20.2M 12.25%
4,049,298
-1,092,448
-21% -$4.78M
APEN
3
DELISTED
Apollo Endosurgery, Inc.
APEN
$18M 10.93%
2,577,996
– –
AMRN
4
Amarin Corp
AMRN
$292M
$17.5M 10.65%
283,510
-4,569
-2% -$283K
VNDA icon
5
Vanda Pharmaceuticals
VNDA
$327M
$11.4M 6.95%
600,000
-384,584
-39% -$6.43M
VIVE
6
DELISTED
VIVEVE MED INC
VIVE
$10.5M 6.36%
3,850
– –
CPIX icon
7
Cumberland Pharmaceuticals
CPIX
$102M
$7.38M 4.48%
1,203,339
-119,702
-9% -$749K
CORV
8
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$7.29M 4.43%
1,930,022
-1,311,528
-40% -$3.42M
ALIM
9
DELISTED
Alimera Sciences
ALIM
$6.83M 4.15%
465,412
+53,410
+13% +$751K
NVLN
10
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$6.6M 4.01%
1,792,911
-67,089
-4% -$269K
HTGM
11
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$5.51M 3.35%
+9,384
New +$6.12M
ISEE
12
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.22M 3.17%
1,912,018
+318,899
+20% +$880K
BDSI
13
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$4.38M 2.66%
1,486,002
-2,220,082
-60% -$5.26M
RIGL icon
14
Rigel Pharmaceuticals
RIGL
$750M
$4.24M 2.57%
+149,659
New +$5.33M
ADMA icon
15
ADMA Biologics
ADMA
$2.02B
$3.75M 2.28%
+831,731
New +$4.15M
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$4.38B
$2.98M 1.81%
+194,900
New +$3.48M
ATEC icon
17
Alphatec Holdings
ATEC
$1.31B
$2.69M 1.64%
+903,224
New +$3.21M
ATXS
18
DELISTED
Astria Therapeutics
ATXS
$2.3M 1.4%
+40,000
New +$3.69M
CDTX
19
DELISTED
Cidara Therapeutics
CDTX
$2.21M 1.34%
+21,277
New +$2.01M
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$2.02B
$1.39M 0.85%
+198,373
New +$1.95M
VYNT
21
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$1.24M 0.75%
9,277
-2,541
-22% -$384K
MTVA
22
MetaVia Inc
MTVA
$8.83M
$1.05M 0.64%
2
-2
-50% -$817K
CFMS
23
DELISTED
Conformis, Inc. Common Stock
CFMS
$770K 0.47%
24,644
-86,464
-78% -$2.99M
MLNT
24
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$331K 0.2%
+10,440
New +$376K
NVIV
25
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
$132K 0.08%
+104
New +$571K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Stonepine Capital Management held 40 positions worth $165M, down 12% from $187M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management withdrew a net $24.2M in Q2 2018, closing 15 positions and reducing 11 holdings. Its most notable exit was Dova Pharmaceuticals, Inc. Common Stock, an estimated $4.99M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in HTG Molecular Diagnostics, Inc. Common Stock worth $5.51M.

  • Stonepine Capital Management's largest Q2 2018 buy was HTG Molecular Diagnostics, Inc. Common Stock: 9,384 shares worth $5.51M.
  • Stonepine Capital Management added most to IVERIC bio, Inc. Common Stock in Q2 2018, an estimated $880K increase.
  • Stonepine Capital Management's biggest Q2 2018 reduction was Vanda Pharmaceuticals, cutting an estimated $6.43M.
  • Stonepine Capital Management fully exited Dova Pharmaceuticals, Inc. Common Stock in Q2 2018, selling an estimated $4.99M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $165M portfolio in Q2 2018.
  • Stonepine Capital Management opened 10 new positions and closed 15 in Q2 2018.
  • Stonepine Capital Management's portfolio value fell 12% quarter-over-quarter to $165M.

Based on Stonepine Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.